When your neuromodulation product is ready for market testing, the University of Minnesota can help to make your new technology as successful as possible.
Limited Release
As an advanced stage 4 medical center the University of Minnesota is able to support humanitarian device exemption (HDE) products, i.e. Medtronics DBS to treat Dystonia, or limited release therapies prior to a full premarket approval, for example NeuroPace's responsive neurostimulation for epilepsy.
Contact Dwight Nelson for more information
Medical Industry Valuation Lab
This five-week product market analysis offers a secure, unbiased market assessment of your innovation. By combining graduate-student perspectives on intellectual property, market size, regulatory approvals, reimbursement requirements, and financial return, you can gain novel insights into your project's prospects. This program is part of the Medical Industry Leadership Institute (MILI) at the Carlson School of Management.
Contact Greg Peterson for more information.
Featured Project: NeuroPace
The University of Minnesota is a key partner for the use of advanced and limited novel sophisticated neuro therapies in patients. Many new products have safety restrictions that do not allow for their use at all medical centers. For example, as a stage 4 epilepsy care center, the Univerisity of Minnesota Medical Center is able to implant NeuroPace, a neurostimulator to monitor and respond to seizures. Safety information on the NeuroPace website states that it should only be implanted at a comprehensive epilepsy center by skilled neurosurgeons. Epilepsy experts at the University are able to help many patients affected by epilepsy because of our highly equipped facilities and physicians. In addition, by implanting NeuroPace and recording the clinical benefits to patients, NeuroPace can be further evaluated and improved to increase access to all patients.